JosÃ© M GonzÃ¡lez-Navajas

List of Publications by Year
in descending order

54 papers	4,054 citations	257450 24 h-index	161849 54 g-index
56 all docs	56 docs citations	56 times ranked	8414 citing authors

#	Article	IF	Citations
1	Absent in Melanoma 2 (AIM2) Regulates the Stability of Regulatory T Cells. International Journal of Molecular Sciences, 2022, 23, 2230.	4.1	10
2	The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies. Frontiers in Immunology, 2021, 12, 625783.	4.8	34
3	The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy. Frontiers in Immunology, 2021, 12, 625667.	4.8	32
4	Functionality of beta-adrenergic receptors in patients with cirrhosis treated chronically with non-selective beta-blockers. Hepatology International, 2020, 14, 858-868.	4.2	3
5	The Emerging Relevance of AIM2 in Liver Disease. International Journal of Molecular Sciences, 2020, 21, 6535.	4.1	21
6	Liver Sinusoidal Endothelial Cells Contribute to Hepatic Antigen-Presenting Cell Function and Th17 Expansion in Cirrhosis. Cells, 2020, 9, 1227.	4.1	13
7	Inhibition of IRF4 in dendritic cells by PRR-independent and -dependent signals inhibit Th2 and promote Th17 responses. ELife, 2020, 9, .	6.0	24
8	Improved hemodynamic and liver function in portal hypertensive cirrhotic rats after administration of B. pseudocatenulatum CECT 7765. European Journal of Nutrition, 2019, 58, 1647-1658.	3.9	13
9	Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. FASEB Journal, 2019, 33, 11595-11605.	0.5	68
10	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	2.9	766
11	Bacterial DNA translocation contributes to systemic inflammation and to minor changes in the clinical outcome of liver transplantation. Scientific Reports, 2019, 9, 835.	3.3	16
12	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2019, 25, 1357-1366.	1.9	5
13	Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. Liver International, 2018, 38, 295-302.	3.9	12
14	Regulatory T Cells Restrict Permeability to Bacterial Antigen Translocation and Preserve Shortâ€€hain Fatty Acids in Experimental Cirrhosis. Hepatology Communications, 2018, 2, 1610-1623.	4.3	15
15	Treatment with nonâ€€selective betaâ€€blockers affects the systemic inflammatory response to bacterial <scp>DNA</scp> in patients with cirrhosis. Liver International, 2018, 38, 2219-2227.	3.9	17
16	AIM2 deficiency reduces the development of hepatocellular carcinoma in mice. International Journal of Cancer, 2018, 143, 2997-3007.	5.1	30
17	Toll-like receptor polymorphisms compromise the inflammatory response against bacterial antigen translocation in cirrhosis. Scientific Reports, 2017, 7, 46425.	3.3	24
18	The expression and activation of the AIM2 inflammasome correlates with inflammation and disease severity in patients with acute pancreatitis. Pancreatology, 2017, 17, 364-371.	1.1	18

#	Article	IF	Citations
19	IL26 modulates cytokine response and anti-TNF consumption in Crohnâ€™s disease patients with bacterial DNA. Journal of Molecular Medicine, 2017, 95, 1227-1236.	3.9	9
20	Lactulose reduces bacterial <scp>DNA</scp> translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver International, 2017, 37, 212-223.	3.9	28
21	Selective intestinal decontamination with norfloxacin enhances a regulatory T cellâ€mediated inflammatory control mechanism in cirrhosis. Liver International, 2016, 36, 1811-1820.	3.9	12
22	The digestive tract as the origin of systemic inflammation. Critical Care, 2016, 20, 279.	5.8	92
23	Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis. European Journal of Nutrition, 2016, 55, 197-206.	3.9	23
24	Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohnâ€™s Disease. American Journal of Gastroenterology, 2016, 111, 529-540.	0.4	34
25	Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis. Journal of Hepatology, 2016, 64, 135-145.	3.7	31
26	Inflammasome activation in decompensated liver cirrhosis. World Journal of Hepatology, 2016, 8, 207.	2.0	11
27	Dual-specificity phosphatase 6 regulates CD4+ T-cell functions and restrains spontaneous colitis in IL-10-deficient mice. Mucosal Immunology, 2015, 8, 505-515.	6.0	42
28	Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 147-154.	2.8	25
29	Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohnâ€™s disease. Journal of Gastroenterology, 2015, 50, 758-768.	5.1	10
30	Absent in melanoma 2 triggers a heightened inflammasome response in ascitic fluid macrophages of patients with cirrhosis. Journal of Hepatology, 2015, 62, 64-71.	3.7	41
31	Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis. World Journal of Gastroenterology, 2015, 21, 11493.	3.3	16
32	Protective effect of Bifidobacterium pseudocatenulatum <scp>CECT</scp>7765 against induced bacterial antigen translocation in experimental cirrhosis. Liver International, 2014, 34, 850-858.	3.9	41
33	The immediate protective response to microbial challenge. European Journal of Immunology, 2014, 44, 2536-2549.	2.9	8
34	Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut, 2014, 63, 272-280.	12.1	62
35	The ion channel TRPV1 regulates the activation and proinflammatory properties of CD4+ T cells. Nature Immunology, 2014, 15, 1055-1063.	14.5	193
36	Role of interleukin 10 in norfloxacin prevention of luminal free endotoxin translocation in mice with cirrhosis. Journal of Hepatology, 2014, 61, 799-808.	3.7	15

#	Article	IF	Citations
37	Modulation of Inflammatory Response in a Cirrhotic Rat Model with Induced Bacterial Peritonitis. PLoS ONE, 2013, 8, e59692.	2.5	3
38	Autophagy Suppresses Interleukin-1Î² (IL-1Î²) Signaling by Activation of p62 Degradation via Lysosomal and Proteasomal Pathways. Journal of Biological Chemistry, 2012, 287, 4033-4040.	3.4	82
39	Type I Interferons Maintain Foxp3 Expression and T-Regulatory Cell Functions Under Inflammatory Conditions in Mice. Gastroenterology, 2012, 143, 145-154.	1.3	72
40	Beta-Adrenergic Receptor 1 Selective Antagonism Inhibits Norepinephrine-Mediated TNF-Alpha Downregulation in Experimental Liver Cirrhosis. PLoS ONE, 2012, 7, e43371.	2.5	12
41	Immunomodulatory functions of type I interferons. Nature Reviews Immunology, 2012, 12, 125-135.	22.7	843
42	ERK activation drives intestinal tumorigenesis in Apcmin/+ mice. Nature Medicine, 2010, 16, 665-670.	30.7	182
43	Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9â€“driven antiinflammatory cytokine production. Journal of Experimental Medicine, 2010, 207, 2799-2807.	8.5	64
44	Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10638-10643.	7.1	146
45	TLR4 signaling in effector CD4+ T cells regulates TCR activation and experimental colitis in mice. Journal of Clinical Investigation, 2010, 120, 570-581.	8.2	143
46	THE PROTECTIVE EFFECTS OF TYPE-1 INTERFERON IN MODELS OF INTESTINAL INFLAMMATION. Advances in Experimental Medicine and Biology, 2009, 633, 1-6.	1.6	3
47	Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology, 2008, 47, 978-985.	7.3	152
48	Serum and ascitic fluid bacterial DNA: A new independent prognostic factor in noninfected patients with cirrhosis. Hepatology, 2008, 48, 1924-1931.	7.3	141
49	Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. Journal of Hepatology, 2008, 48, 61-67.	3.7	61
50	Bacterial translocation is downregulated by anti-TNF-Î± monoclonal antibody administration in rats with cirrhosis and ascites. Journal of Hepatology, 2007, 46, 797-803.	3.7	48
51	Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. Clinical and Experimental Immunology, 2007, 150, 230-237.	2.6	32
52	Bacterial DNA Induces the Complement System Activation in Serum and Ascitic Fluid from Patients with Advanced Cirrhosis. Journal of Clinical Immunology, 2007, 27, 438-444.	3.8	36
53	The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology, 2006, 44, 633-639.	7.3	88
54	A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology, 2004, 39, 484-491.	7.3	132